Five ways the wiki draws an idea
Dark teal glass on a light page, after the My-Pepts graphics. Every one below is live, drawn from the retatrutide page's own data, and each says in text what it shows.
Type 1
Steps
A short sequence that has a real order: reconstitution, how a trial is run, how a compound reaches a license. Cards arrive along a rail, once.
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
Type 2
Orbit
One thing and what it acts on: a molecule and its receptors, a blend and its parts. Lines flow outward; picking a node explains it.
One molecule, what it acts on
What it binds, and what each receptor is known to do. Pick one.
GIP receptor. In vitro the molecule is more active here than at the other two receptors. In obese mice the discovery paper credits GIP and GLP-1 receptor activity with the reduction in calorie intake 6.
Type 3
Trial bars
Results by arm of a published trial, switched by outcome. Comparators are pink. A hidden table carries the same numbers for screen readers.
What the trials measured
Each bar is one arm of a published trial: the mean change in the group assigned that amount. Pick an outcome.
Change in body weight at 48 weeks
| Arm | Mean change |
|---|---|
| Placebo (comparator) | -2.1% |
| 1 mg | -8.7% |
| 4 mg | -17.1% |
| 8 mg | -22.8% |
| 12 mg | -24.2% |
Least-squares mean percentage change from baseline in the phase 2 obesity trial, 338 adults. The 4 mg and 8 mg figures pool two arms that differed only in starting dose.
Pink bars are comparator arms. Results of a trial are averages across a monitored group, not a forecast for a person.
Type 4
Timeline ribbon
A compound's history, year by year, lighting in order along a line. Scrolls sideways on a phone.
From first trial to today
Retatrutide: year by year. Scroll sideways for the whole ribbon.
- 2019
The phase 1b trial in type 2 diabetes begins enrolling in December, at four centers in the USA 5.
- 2021
The phase 2 obesity trial is registered and randomizes its first participants; the phase 2 diabetes trial begins 210.
- 2022
The discovery paper and the phase 1b results are published under the code LY3437943 56.
- 2023
The phase 2 results in obesity and in type 2 diabetes are published 12.
- 2024
The MASLD substudy is published; TRANSCEND-T2D-1 begins randomizing; a head-to-head trial against tirzepatide is registered 3412.
- 2025
A systematic review and meta-analysis pools four placebo-controlled trials 7.
- 2026
The TRANSCEND-T2D-1 results and the TRANSCEND-CKD design paper are published 49.
Type 5
Evidence ladder
Where a compound stands between cell studies and a licensed medicine, with what PubMed holds. It is on every compound page, stubs included.
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3: Retatrutide
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies
First studies in people: safety, and how the body handles it.
- Cells and animals
Laboratory and animal work. An animal result is not a result in people.
- 219
- papers on PubMed
- 133
- of them in people
- 11
- randomized trials
- 136
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
And in three dimensions
The bead chain
Every compound has its own chain, grown from its name: the wiki's picture of a peptide. On a wide screen it turns slowly in 3D and leans toward the pointer; on a phone, with reduced motion or without WebGL it is a still drawing.
Open this page on a wider screen to see it turn.